EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vigeo Promotes Myotube Differentiation and Protects Dexamethasone-Induced Skeletal Muscle Atrophy via Regulating the Protein Degradation, AKT/mTOR, and AMPK/Sirt-1/PGC1α Signaling Pathway In Vitro and In Vivo

Yoon-Hee Cheon, Chang-Hoon Lee, Chong-Hyuk Chung iD, Ju-Young Kim iD, Myeung-Su Lee

Nutrients · 13.08.2024 · 16 (16) · 2687

DOI: 10.3390/nu16162687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, online erschienen am 13.08.2024. Verfasst von Yoon-Hee Cheon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, 460 Iksandae-ro, Iksan 54538, Republic of Korea. Hauptthemen laut MEDLINE: Dexamethasone, Muscular Atrophy, Signal Transduction, Muscle Fibers, Skeletal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sarcopenia, a condition caused by an imbalance between muscle growth and loss, can severely affect the quality of life of elderly patients with metabolic, inflammatory, and cancer diseases. Vigeo, a nuruk-fermented extract of three plants (Eleutherococcus senticosus Maxim (ESM), Achyranthes japonica (Miq.) Nakai (AJN), and Atractylodes japonica Koidzumi (AJK)) has been reported to have anti-osteoporotic effects. However, evidence of the effects of Vigeo on muscle atrophy is not available. Here, in the in vivo model of dexamethasone (Dex)-induced muscle atrophy, Vigeo treatment significantly reversed Dex-induced decreases in calf muscle volume, gastrocnemius (GA) muscle weight, and histological cross-section area. In addition, in mRNA and protein analyses isolated from GA muscle, we observed that Vigeo significantly protected against Dex-induced mouse muscle atrophy by inhibiting protein degradation regulated by atrogin and MuRF-1. Moreover, we demonstrated that Vigeo significantly promoted C2C12 cell line differentiation, as evidenced by the increased width and length of myotubes, and the increased number of fused myotubes with three or more nuclei. Vigeo alleviated the formation of myotubes compared to the control group. Vigeo also significantly increased the mRNA and protein expression of myosin heavy chain (MyHC), MyoD, and myogenin compared to that in the control. Vigeo treatment significantly reduced the mRNA and protein expression of muscle degradation markers atrogin-1 and muscle RING Finger 1 (MuRF-1) in the C2C12 cell line in vitro. Vigeo also activated the AMP-activated protein kinase (AMPK)/silent information regulator 1 (Sirt-1)/peroxisome proliferator-activated receptor-γ co-activator-1α (PGC1α) mitochondrial biogenesis pathway and the Akt/mTOR protein synthesis signaling pathway in Dex-induced myotube atrophy. These findings suggest that Vigeo may have protective effects against Dex-induced muscle atrophy. Therefore, we propose Vigeo as a supplement or potential therapeutic agent to prevent or treat sarcopenia accompanied by muscle atrophy and degeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneMuscular AtrophySignal TransductionMuscle Fibers, SkeletalProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaCell DifferentiationSirtuin 1AMP-Activated Protein KinasesAnimalsMicePlant ExtractsMaleProteolysisMuscle ProteinsMuscle, SkeletalCell LineSKP Cullin F-Box Protein LigasesMice, Inbred C57BLUbiquitin-Protein LigasesTripartite Motif Proteins

Stichwörter der Autor:innen

Vigeodexamethasonemuscle atrophynuruk fermentationsarcopenia

Substanzen

DexamethasoneProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSirtuin 1AMP-Activated Protein KinasesPpargc1a protein, mousePlant ExtractsmTOR protein, mouseMuscle Proteins

Autor:innen und Institutionen

  • Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, 460 Iksandae-ro, Iksan 54538, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, 460 Iksandae-ro, Iksan 54538, Republic of Korea.

ORCID-Profile: Chong-Hyuk Chung, Ju-Young Kim

Förderung

  • Korea Health Industry Development Institute (KHIDI)
  • Ministry of Health and Welfare, Republic of Korea

Zitieren

APA

Cheon, Y. H., Lee, C. H., Chung, C. H., Kim, J. Y., & Lee, M. S. (2024). Vigeo Promotes Myotube Differentiation and Protects Dexamethasone-Induced Skeletal Muscle Atrophy via Regulating the Protein Degradation, AKT/mTOR, and AMPK/Sirt-1/PGC1α Signaling Pathway In Vitro and In Vivo. Nutrients, 16(16), 2687. https://doi.org/10.3390/nu16162687

Vancouver

Cheon YH, Lee CH, Chung CH, Kim JY, Lee MS. Vigeo Promotes Myotube Differentiation and Protects Dexamethasone-Induced Skeletal Muscle Atrophy via Regulating the Protein Degradation, AKT/mTOR, and AMPK/Sirt-1/PGC1α Signaling Pathway In Vitro and In Vivo. Nutrients. 2024;16(16):2687. doi:10.3390/nu16162687

BibTeX
@article{Cheon2024,
  author = {Cheon, Yoon-Hee and Lee, Chang-Hoon and Chung, Chong-Hyuk and Kim, Ju-Young and Lee, Myeung-Su},
  title = {Vigeo Promotes Myotube Differentiation and Protects Dexamethasone-Induced Skeletal Muscle Atrophy via Regulating the Protein Degradation, AKT/mTOR, and AMPK/Sirt-1/PGC1α Signaling Pathway In Vitro and In Vivo},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {16},
  pages = {2687},
  doi = {10.3390/nu16162687}
}
Kostenlos starten →